15:50-16:50 SATELLITE SYMPOSIUM:
Utilization of MRD assessment in the clinical management of CLL patients
Chair: Barbara Eichhorst (Cologne)
Speakers: Barbara Eichhorst (Cologne), Lanny Kirsch (Seattle), Anna Schuh (Oxford)
This symposium is organised and funded by Adaptive Biotechnologies.
16:50-17:50 Meet the Expert session
Resistance to ibrutinib: what to do Jennifer Brown (Boston)/Anna Schuh (Oxford)
16:50-17:50 Biology Poster Walk:
Leaders: Alexey Danilov (Duarte), Davide Rossi (Bellinzona)
Wednesday, November 18, 2020
SESSION V – The increasing role of the leukaemic microenvironment
Chairs: Silvia Deaglio (Turin), Adrian Wiestner (Bethesda)
14:30-14:35 Introduction Silvia Deaglio (Turin)
Adrian Wiestner (Bethesda)
14:35-14:50 Role of stromal cells Andrea Brendolan (Milan)
14:50-15:05 Hypoxia, metabolic reprogramming and
immunosuppression occurring in CLL niche Silvia Deaglio (Turin)
15:05-15:20 Role of T cells Arnon Kater (Amsterdam)
15:20-15:35 Immunomodulatory effects of kinase inhibitors Adrian Wiestner (Bethesda)
SHORT ORAL COMMUNICATION
15:35-15:42 Expansion of antitumor cytotoxic CD8+ T cells
in CLL patients treated with ibrutinib Maria Joao Baptista (Badalona)
15:42-16:12 General discussion
SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL
Chairs: Matthew Davids (Boston), Peter Dreger (Heidelberg)
16:15-16:20 Introduction Matthew Davids (Boston)
Peter Dreger (Heidelberg)
16:20-16:35 Next generation PI3K inhibitors Peter Hillmen (Leeds)
16:35-16:50 Novel inhibitors at preclinical level Alexey Danilov (Duarte)
(MCL1 & CDK inhibitors)
16:50-17:05 Mechanistic effects of BH3 Mimetics in CLL Eric Eldering (Amsterdam)
3